BRAF and melanoma: This is especially true for patients who show no benefit after standard of care, become resistant or belong to somatic mutation subgroups for which no targeted therapy option exists, such as BRAF wild-type melanomas including NRAS mutant and NF1 loss-of-function melanomas.